Yigan mingmu decoction treats diabetic retinopathy via Müller cell autophagy: A network pharmacology study - PubMed
3 hours ago
- #network pharmacology
- #diabetic retinopathy
- #autophagy
- Yigan Mingmu (YGMM) Decoction was studied for its mechanism in treating diabetic retinopathy (DR) via Müller cell autophagy.
- UHPLC-HRMS analysis identified 426 active components in YGMM Decoction, with 181 absorbed into the bloodstream.
- Network pharmacology analysis revealed 166 active compounds targeting 240 genes, with 174 overlapping DR-related targets.
- Key targets included TXNIP and LC3-II, with enrichment analysis pointing to oxidative stress and AGE-RAGE signaling pathways.
- Molecular docking confirmed high binding affinity of primary active ingredients (e.g., quercetin, kaempferol) to their targets.
- In vivo and in vitro studies showed YGMM downregulated Caspase-3, TXNIP, and LC3-II/I ratio dose-dependently (p<0.05).
- Medium-dosage YGMM exhibited optimal therapeutic efficacy in alleviating DR via TXNIP and LC3-II/I autophagy modulation.